Joseph Torresi

University of Melbourne — Australia

Medicine · Health Sciences

50h-index8.0kcitations233works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis B Virus Studies(81), Hepatitis C virus research(76), Travel-related health issues(52), Hepatitis Viruses Studies and Epidemiology(34), Liver Disease Diagnosis and Treatment(29)

Publications233 total

Air–Liquid-Interface-Differentiated Human Nose Epithelium: The Benchmark Culture Model for SARS-CoV-2 Infection
Organoids·2025Open Access
Spectroscopic Characterization and Differentiation of SARS-CoV-2 Virus-like Particles
Analytical Chemistry·2025· 1 cited
Adenovirus vectors can infect mouse megakaryocytes – implications for vaccine-induced thrombosis/thrombocytopenia
Research and Practice in Thrombosis and Haemostasis·2025Open Access
Development of Methods to Produce SARS CoV‐2 Virus‐Like Particles at Scale
Biotechnology and Bioengineering·2025· 3 citedOpen Access
A Robust Human Liver Organoid Model of Hepatitis B Virus Infection
Methods in molecular biology·2025
Development of methods to purify SARS CoV-2 Virus-like particles at scale
2024
Preclinical evaluation of a cross-protective ß-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59
2024· 1 citedOpen Access
Immune imprinting of SARS-CoV-2 responses: changing first immune impressions
mSphere·2024· 11 citedOpen Access
Human Nasal Epithelium Organoids for Assessing Neutralizing Antibodies to a Protective SARS-CoV-2 Virus-like Particle Vaccine
Organoids·2024· 11 citedOpen Access
Preclinical Evaluation of a Cross-Protective ß-SARS-CoV-2 Virus-Like Particle Vaccine Adjuvanted with MF59
SSRN Electronic Journal·2024Open Access
377. Phase I trial of two novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as 4th dose boosters
Open Forum Infectious Diseases·2023Open Access
Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster
EBioMedicine·2023· 16 citedOpen Access
Adenovirus vector produced Zika virus-like particles induce a long-lived neutralising antibody response in mice
Vaccine·2023· 5 citedOpen Access
Development of virus-like particles with inbuilt immunostimulatory properties as vaccine candidates
Frontiers in Microbiology·2023· 15 citedOpen Access
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine
EBioMedicine·2023· 16 citedOpen Access
Interim Results from a Phase I Trial of Novel SARS-CoV-2 Beta Variant Receptor-Binding Domain Recombinant Protein and mRNA Vaccines as a 4<sup>th</sup> Dose Booster
SSRN Electronic Journal·2023· 1 citedOpen Access
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine
2022· 1 citedOpen Access
A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses
Frontiers in Immunology·2022· 16 citedOpen Access
Organoid Models of SARS-CoV-2 Infection: What Have We Learned about COVID-19?
Organoids·2022· 22 citedOpen Access
Air-Liquid-Interface Differentiated Human Nose Epithelium: A Robust Primary Tissue Culture Model of SARS-CoV-2 Infection
International Journal of Molecular Sciences·2022· 37 citedOpen Access
page 1 of 12Next →

Frequent Co-authors

Karin Leder(11), C.–Thomas Bock(9), Stephen Locarnini(8), Annelies Wilder‐Smith(7), Ruth Chin(7), Frank von Sonnenburg(6), L. Earnest-Silveira(6), Eli Schwartz(6), Kevin C. Kain(5), D. O’Brien(5), Graham Brown(5), Brendon Y. Chua(5), Leisa Weld(4), Jim Black(4), David C. Jackson(4), David O. Freedman(4), Michael P. Manns(4), Christian Trautwein(4), Francesco Castelli(4), Philippe Gautret(4)